247 related articles for article (PubMed ID: 22271896)
21. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study.
Sweetenham JW; Goldman B; LeBlanc ML; Cook JR; Tubbs RR; Press OW; Maloney DG; Fisher RI; Rimsza LM; Braziel RM; Hsi ED
Ann Oncol; 2010 Jun; 21(6):1196-1202. PubMed ID: 19875761
[TBL] [Abstract][Full Text] [Related]
23. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
24. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
25. Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol.
Váróczy L; Zilahi E; Gyetvai A; Kajtár B; Gergely L; Sipka S; Illés A
Pathol Oncol Res; 2012 Jan; 18(1):43-8. PubMed ID: 21667346
[TBL] [Abstract][Full Text] [Related]
26. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
27. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
[TBL] [Abstract][Full Text] [Related]
28. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.
Weng WK; Levy R
Leuk Lymphoma; 2009 May; 50(5):723-7. PubMed ID: 19452316
[TBL] [Abstract][Full Text] [Related]
29. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.
Vidal L; Gafter-Gvili A; Leibovici L; Dreyling M; Ghielmini M; Hsu Schmitz SF; Cohen A; Shpilberg O
J Natl Cancer Inst; 2009 Feb; 101(4):248-55. PubMed ID: 19211444
[TBL] [Abstract][Full Text] [Related]
30. Correlation of FcγRIIIa Polymorphisms to the Response of Rituximab in Thai Patients with Diffuse Large B-Cell Lymphoma.
Angsirisak N; Wittayalertpanya S; Limpanasithikul W; Bunworasate U; Owattanapanich D
J Med Assoc Thai; 2015 Dec; 98(12):1215-21. PubMed ID: 27004307
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
32. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.
Forero-Torres A; de Vos S; Pohlman BL; Pashkevich M; Cronier DM; Dang NH; Carpenter SP; Allan BW; Nelson JG; Slapak CA; Smith MR; Link BK; Wooldridge JE; Ganjoo KN
Clin Cancer Res; 2012 Mar; 18(5):1395-403. PubMed ID: 22223529
[TBL] [Abstract][Full Text] [Related]
33. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
34. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
35. Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.
Kenkre VP; Hong F; Cerhan JR; Lewis M; Sullivan L; Williams ME; Gascoyne RD; Horning SJ; Kahl BS
Clin Cancer Res; 2016 Feb; 22(4):821-6. PubMed ID: 26510856
[TBL] [Abstract][Full Text] [Related]
36. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
[TBL] [Abstract][Full Text] [Related]
37. Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies.
Seiler T; Hiddemann W; Dreyling M
Immunotherapy; 2009 Nov; 1(6):1015-24. PubMed ID: 20635916
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
Czuczman MS; Leonard JP; Jung S; Johnson JL; Hsi ED; Byrd JC; Cheson BD
Ann Oncol; 2012 Sep; 23(9):2356-2362. PubMed ID: 22357442
[TBL] [Abstract][Full Text] [Related]
39. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.
Mir MA; Maurer MJ; Ziesmer SC; Slager SL; Habermann T; Macon WR; Link BK; Syrbu S; Witzig T; Friedberg JW; Press O; LeBlanc M; Cerhan JR; Novak A; Ansell SM
Blood; 2015 Feb; 125(6):992-8. PubMed ID: 25422100
[TBL] [Abstract][Full Text] [Related]
40. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.
Magni M; Di Nicola M; Devizzi L; Matteucci P; Lombardi F; Gandola L; Ravagnani F; Giardini R; Dastoli G; Tarella C; Pileri A; Bonadonna G; Gianni AM
Blood; 2000 Aug; 96(3):864-9. PubMed ID: 10910898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
